Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Digital Medicine and Medtech Showcase (January 2019)
14 slides from Vivani Medical's conference presentation, Jan 9, 2019
Slide 1: Second Sight Medical Products, Inc. - Digital Medicine and Medtech Showcase
jecond Sight Medical Products, Inc. Digital Medicine and Medtech Showcase January 9, 2019 SEC@NDSIGHT (NASDAQ: EYES)
Slide 2: Forward Looking Statements
vard Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the 'safe harbor created by those se
Slide 3: Argus II Retinal Prosthesis and Orion Visual Cortical Prosthesis
DUG Argus? Orion® Retinal Prosthesis Visual Cortical Prosthesis + Firstand only FDA approved retinal prosthesis, + ~$200million and 20+ years invested to develop ‘and commercialize + Established technology with 293+ implants + Approved for individuals with advanced retinitis h Technology + Transform
Slide 4: Argus II: Effective Treatment for Blindness
Argus® Il: Effective Treatment for Blindness Argus® II is a retinal prosthesis that induces visual perception in individuals with severe to profound retinitis pigmentosa (RP) SECONDSIGHT Video Link: https://youtu.be/e2VNMO5GeUE SECONDSIGHT
Slide 5: Execute Orion clinical and R&D programs as our top priority
4 Execute Orion clinical and R&D programs as our top priority * US. feasibility study at UCLA and Baylor is ongoing with six subjects * Orion FDA designated Breakthrough Device for expedited pathway to commercialization Orion + R&D to iterate cortical prosthesis and external components in preparatio
Slide 6: Orion: FDA Breakthrough Device with Potential to Treat Virtually All Forms of Blindness
Orion®: FDA Breakthrough Device with Potential to Treat Virtually All Forms of Blindness The addressable market for Orion is potentially over 70,000 individuals in the U.S.; a multi-billion dollar market opportunity Market outside U.S. expected to be US. larger Approximately Legally blind due to 500
Slide 7: Encouraging Early Orion Feasibility Study Results
Encouraging Early Orion® Feasibility Study Results Feasibility study at Ronald Reagan UCLA Medical Center and the Baylor College of Medicine + Five subjects implanted and activated in 1H 2018 f + Implanting sixth patient at Baylor College of Medicine in January 2019 Early testing indicates performan
Slide 8: Research Technologies to Enhance User Experience
Research Technologies to Enhance User Experience Eye Tracking Depth-Based Decluttering ial) “ ‘ial Recognition Research projects have potential to benefit Argus and Orion users SEC@NDSIGHT
Slide 9: Centers of Excellence model and artificial vision rehabilitation
<@> Centers of Excellence (COE) model and artificial vision rehabilitation + Centers of Excellence mode! to build regional artificial vision centers for Argus and Orion + Best practices development and pioneered post-surgical rehabilitation toimprove patient satisfaction and outcomes forall artitiia
Slide 10: Retinitis Pigmentosa
Retinitis Pigmentosa ye Traumafinjury Glaveoma Diabetic Retinopathy Optic Nerve Disease Enhancements to User Experience ommercial alidation Study Higher electrode count, bilateral implants SEC@NDSIGHT
Slide 11: Key Drivers of Shareholder Value through 2019
Key Drivers of Shareholder Value through 2019 Orion Release interim data from first six subjects of HBF feasibility tial Agreement w/ FDA for Orion clinical & = Agreement on pivotal and post-market trial designs Regulatory Pathway Via the FDA's Breakthrough Device Program Orion Feasibility =, Study
Slide 12: Select Financial Data
Select Financial Data rv2o7 | FY2016 Implants 69 75 42 Revenue $6,500-$6,949' $7,964 $3,985 Gross Profit (Loss) $2,847 $(6.091) Net Loss Pending $(28,516) $83,179) Non-GAAP Adjusted Net Loss? $(27,576) $(24,812) 1) Non-GAAP adjustednet oss excludes non-cashexpenses including stock based compensation
Slide 13: Second Sight Investment Highlight
Second Sight Investment Highlight Orion is a large market opportunity that is more than 50x the current RP market + Potential to treat nearly all forms of blindness including diabetic retinopathy, glaucoma, optic nerve disease and eye injury + Feasibility study at UCLA and Baylor underway with good
Slide 14: Contacts
Contacts ‘Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 Wwww.secondsight.com Will McGuire President & CEO Direct: 818-833-5040 wmeguire@secondsight.com fail Investor Relations Institutional Investor Relations Greg Falesnik Lisa Wilson Manag
Second Sight Medical Products — Digital Medicine and Medtech Showcase (January 2019) on 6ix